ストックスクリーナーアプリを入手
272.67
1.94%
5.20
プレマーケット:
276.00
3.33
+1.22%
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - simplywall.st
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses - simplywall.st
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com - Investing.com South Africa
Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings - Quiver Quantitative
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD - Investing.com
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - GlobeNewswire Inc.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), Alnylam Pharma (ALNY) and Elevance Health (ELV) - The Globe and Mail
Alnylam Pharmaceuticals (ALNY) Proxy filing Summary - Quartr
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth - ChartMill
Liquidity Mapping Around (ALNY) Price Events - Stock Traders Daily
Alnylam schedules conference call on second-quarter 2026 results - Bitget
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - BioSpace
Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak - Trefis
Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - Moomoo
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY) - Seeking Alpha
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - The National Law Review
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease - BioSpace
ALNY Maintained by B of A Securities -- Price Target Lowered to $410 - GuruFocus
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating - Moomoo
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says - Moomoo
Stifel reiterates Buy rating on Alnylam stock amid trial debate By Investing.com - Investing.com Canada
BofA cuts Alnylam stock price target on conservative outlook By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill
Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co. - Moomoo
ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410 - GuruFocus
ALNY Maintained by HC Wainwright & Co. -- Price Target Raised to $485 - GuruFocus
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - MarketBeat
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $485 - Moomoo
Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Strong Buy Opportunity with 47% Upside Potential - DirectorsTalk Interviews
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships - Sahm
Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure - Sahm
Truist Financial Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating - Moomoo
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/Ionis - MSN
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations? - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up - 24/7 Wall St.
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)? - Yahoo Finance
3 Healthcare Stocks Investors Are Turning To As Growth Valuations Look Stretched - Sahm
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails - Yahoo Finance
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $400 to $468 - Moomoo
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns - Yahoo Finance
Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $446.43, Implies 38% Upside - TradingView
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha
Alnylam, BridgeBio Gain From AstraZeneca-Ionis Drug Missing Target -- Market Talk - Moomoo
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction - Barron's
Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating - Moomoo
Stifel maintains Alnylam Pharmaceuticals (ALNY) buy recommendation - MSN
Alnylam jumps as rival ATTR-CM setback appears to strengthen Amvuttra outlook - Quiver Quantitative
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook - Seeking Alpha
Why is Alnylam Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
ALNY Stock Rallies As RNAi Expansion And AI Deals Deepen - StocksToTrade
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study - Yahoo Finance
Thursday's Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges - Blockonomi
3.10%
大文字化:
|
ボリューム (24 時間):